Last updated on April 2017

Study of LN-145 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma


Brief description of study

Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent and/or metastatic cervical carcinoma

Detailed Study Description

LN-145 is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI, for the treatment of patients with recurrent and/or metastatic cervical carcinoma. The cell transfer therapy used in this study involves patients receiving a NMA lymphocyte depleting preparative regimen, followed by infusion of autologous TIL followed by the administration of a regimen of IL-2.

Clinical Study Identifier: NCT03108495

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Lion Biotechnologies Study Team

Lion Cervical Investigative Site
Tampa, FL United States
  Connect »

Lion Biotechnologies Study Team

Lion Cervical Investigative Site
Buffalo, NY United States
  Connect »

Lion Biotechnologies Study Team

Lion Cervical Investigative Site
Pittsburgh, PA United States
  Connect »